PSB-15160
PSB-15160 is a human GPR84 agonist with EC50 values of 0.0800 μM and 4.33 μM, and selectivity versus FFAR1, FFAR4, and arylhydrocarbon receptor. PSB-15160 exhibits biased agonism, ago-allosteric action, and structure-activity relationships differing between cAMP and β-arrestin assays. PSB-15160 shows increased stability relative to the lead structure 3,3'-diindolylmethane.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 215997-93-6
- 分子式: C17H12F2N2
- 分子量:282.29
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
IC50 & Target
[1]|
GPR84 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | EC50 |
0.199 μM
Compound: 89; PSB-15160
|
Positive allosteric modulation of recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as increase in [3H]PSB-1584 binding measured after 6 hrs by scintillation counting method
Positive allosteric modulation of recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as increase in [3H]PSB-1584 binding measured after 6 hrs by scintillation counting method
|
[PMID: 31721581] |
体外実験
PSB-15160 (compound 38) (preincubated for 5 min; Forskolin (HY-15371) 10 μM; additional 15 min) inhibits Forskolin-induced cAMP accumulation in a concentration-dependent manner in CHO cells stably expressing human GPR84, with an EC50 of 80.0 nM and a maximum efficacy of 117% relative to the maximum effect of capric acid[1].
PSB-15160 (preincubation for 5 min; Forskolin 10 μM; additional 15 min) inhibits cAMP accumulation in a concentration-dependent manner in CHO-hGPR84 cells, while no corresponding inhibitory effect is observed in parental CHO cells that do not express GPR84, indicating that this cAMP response is GPR84-dependent[1].
PSB-15160 (90 min; 60 min additional incubation with detection reagent) induces β-arrestin recruitment in CHO-hGPR84 cells, with an EC50 of 4.33 μM and a maximum efficacy of 125% relative to Embelin (HY-17473) (10 μM); its potency in the β-arrestin pathway is approximately 54-fold lower than that in the Gi/cAMP pathway, exhibiting a signaling profile biased toward Gi-mediated adenylate cyclase inhibition[1].
PSB-15160 (10 μM) exhibits virtually no FFAR1 agonistic activity in the calcium mobilization assay using 1321N1 astrocytoma cells recombinantly expressing human FFAR1[1].
PSB-15160 (10 μM; 90 min in agonist assay; additional 60 min for detection) exhibits essentially no agonistic activity in CHO cells recombinantly expressing human FFAR4; after pre-incubation for 30 min prior to the addition of TUG-891 (HY-100881) (4 μM) in an agonist screening assay, PSB-15160 shows no FFAR4 inhibition[1].
PSB-15160 (10 μM) exhibits no agonistic activity at human GPR35, a phylogenetically related receptor of the GPR84 system[1].
PSB-15160 (5, 20 μM; 18 h) only weakly induces the expression of the AhR target gene CYP1A1 in HepG2 cells at 20 μM, and its effect is significantly weaker than that of the lead compound 1; accordingly, the AhR activity of PSB-15160 is markedly reduced relative to its GPR84 agonistic activity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HepG2
-
Concentration:5, 20 μM
-
Incubation Time:18 h
-
Result:Produced only a weak CYP1A1 induction at 20 μM.
Showed markedly weaker AhR-dependent CYP1A1 induction than lead compound 1.
化学情報
-
CAS 番号 215997-93-6
-
分子量 282.29
-
分子式 C17H12F2N2
-
SMILES
FC=1C=CC=2NC=C(C2C1)CC3=CNC=4C=CC(F)=CC43
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)